Q03181 (PPARD_HUMAN) Homo sapiens (Human)

Peroxisome proliferator-activated receptor delta UniProtKBInterProSTRINGInteractive Modelling

441 aa; Sequence (Fasta) ; (Isoform 2; Isoform 3; Isoform 4)
Identical sequences: Homo sapiens: A0A024RCW6

Available Structures

44 Experimental Structures

DescriptionOligo-stateLigandsStructureRange
Human PPAR delta ligand binding domain in complex with a synthetic agonist TIPP401homo-2-merB7G;401;170-441
Assess
MOLECULAR RECOGNITION OF FATTY ACIDS BY PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORShomo-2-merEPA;171-441
Assess
MOLECULAR RECOGNITION OF FATTY ACIDS BY PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORShomo-2-mer433;171-441
Assess
Human PPAR delta ligand binding domain in complex with a synthetic agonist TIPP204homo-2-merB7G;K55;170-440
Assess
Human Peroxisome proliferator-activated receptor (PPAR) delta in complexed with a potent and select…homo-2-mer8RR;K;CL;PGO;JZR;173-441
Assess
Human Nuclear Receptor-Ligand Complex 1homo-2-merB7G;VCA;174-441
Assess
Co-crystal structure of an Inhibitor in complex with human PPARdelta LBDhomo-2-mer9LU;171-438
Assess
PPARdelta complexed with an anthranilic acid partial agonisthomo-2-merIOD;DY6;172-439
Assess
Co-crystal structure of Inhibitor compound in complex with human PPARdelta LBDhomo-2-mer89L;172-438
Assess
Crystal Structure of PPAR-delta complexhomo-2-merL41;175-441
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 4monomer7UY;B7G;PGO;PEG;170-440
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 11monomerB7G;7SM;PGO;PEG;170-440
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 7monomerB7G;7U1;PGO;170-440
Assess
Crystal structure PPAR delta binding GW0742monomerGW0;GOL;171-441
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 3monomer7V4;B7G;PGO;PEG;K;170-440
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 12monomer7SS;PGO;PEG;B7G;170-439
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 2monomerB7G;7V1;PGO;PEG;170-439
Assess
Human PPARdelta ligand-binding domain in complexed with GW501516monomerB7G;PGO;PEG;7T1;170-439
Assess
Crystal Structure of Peroxisome Proliferator-Activated Receptor Delta (PPARd)LBD in Complex with DN…monomer9RF;B7G;PE3;171-440
Assess
Crystal structure of PPAR delta complexed with GW2331monomerIOD;331;B7G;170-439
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 1monomer7UJ;B7G;PGO;PEG;K;173-441
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 6monomerB7G;7TY;PEG;PGO;173-441
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 9monomerB7G;7U7;PGO;PEG;171-439
Assess
Crystal Structure of Peroxisome Proliferator-Activated Receptor Delta (PPARd) in Complex with a Ful…monomerB7G;D32;171-439
Assess
Structure of PPARdelta with 3-[5-Methoxy-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-yl]-propionic acidmonomerET1;1BO;172-440
Assess
Structural basis for iloprost as a dual PPARalpha/delta agonistmonomerIL2;173-441
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 10monomer7UA;PGO;PEG;B7G;172-439
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 14monomerB7G;7SY;PEG;PGO;174-441
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 5monomer7TV;PGO;PEG;B7G;172-439
Assess
Novel Sulfonylthiadiazoles with an Unusual Binding Mode as Partial Dual Peroxisome Proliferator-Act…monomerWLM;1PE;173-440
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 8monomer7U4;B7G;PGO;PEG;173-439
Assess
PPARd complexed with a phenoxyacetic acid partial agonistmonomer3EQ;JZR;IOD;173-439
Assess
3,4,5-Trisubstituted Isoxazoles as Novel PPARdelta Agonists: Part2monomerGNI;174-440
Assess
Novel Sulfonylthiadiazoles with an Unusual Binding Mode as Partial Dual Peroxisome Proliferator-Act…monomer08S;BOG;174-440
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 16monomer7UG;PEG;PGO;174-439
Assess
Human Nuclear Receptor-Ligand Complex 2monomerCA;B7G;VCA;175-440
Assess
MOLECULAR RECOGNITION OF FATTY ACIDS BY PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORSmonomer175-440
Assess
PPAR Delta in complex with azppard02monomer3OZ;175-440
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 15monomer7UD;PEG;PGO;B7G;174-438
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 13monomerB7G;PGO;7SV;174-438
Assess
Human Nuclear Receptor-Ligand Complex 1monomerB7G;VCA;175-439
Assess
Novel Sulfonylthiadiazoles with an Unusual Binding Mode as Partial Dual Peroxisome Proliferator-Act…monomerZ00;BOG;176-440
Assess
Ligand binding domain of PPAR delta receptor in complex with a partial agonistmonomer1FA;174-438
Assess
Solution structure of the C4-type zinc finger domain from human Peroxisome proliferator-activated r…monomerZN;72-146
Assess

6 Homology models

Oligo-stateLigandsQMEANDisCoTemplateRangeSeq id (%)
monomerZN;0.733dzy.1.B71-441
65.59
Assess
monomerZN;0.564nqa.1.A69-438
31.27
Assess
monomerZN;0.553dzu.1.A71-437
32.61
Assess
monomerZN;0.544iqr.2.A72-439
29.75
Assess
monomerZN;0.545uan.1.A72-439
31.27
Assess
monomerZN;0.524iqr.2.B72-439
29.75
Assess

14 Homology models built on isoform sequence

IsoformOligo-stateLigandsQMEANDisCoTemplateRangeSeq id (%)
Isoform 2monomerZN;0.673e00.1.B70-360
64.60
Assess
Isoform 2monomerZN;0.585uan.1.B73-360
30.28
Assess
Isoform 2monomerZN;0.534nqa.1.A70-360
34.43
Assess
Isoform 2monomerZN;0.523dzu.1.A71-360
35.66
Assess
Isoform 2monomerZN;0.515uan.1.A72-360
34.43
Assess
Isoform 2monomerZN;0.504iqr.2.B72-360
31.93
Assess
Isoform 3monomerZN;0.723e00.1.B31-402
65.42
Assess
Isoform 3monomerZN;0.573dzu.1.A32-398
32.92
Assess
Isoform 3monomerZN;0.574nqa.1.A28-399
31.69
Assess
Isoform 3monomerZN;0.555uan.1.A33-400
31.69
Assess
Isoform 3monomerZN;0.534iqr.2.B33-400
29.25
Assess
Isoform 3monomerZN;0.534iqr.2.A33-400
29.25
Assess
Isoform 4monomerET1;1BO;0.833et2.1.A74-342
100.00
Assess
Isoform 4monomer0.723dzy.1.B36-343
60.91
Assess

Alignments